News & Press

Suneva Medical Signs Multi-Million dollar Line of Credit Agreement with Western Technology Investment

April 4, 2013

Additional Financing Used to Fund Suneva’s Growth SAN DIEGO, CA – December 17, 2009 – Suneva Medical, a privately-held aesthetic medical device company, today announced that it has signed a multi-million dollar line of credit facility with Western Technology Investment (WTI). The line of credit facility will be used to fund commercial support for Artefill®, …

Suneva Medical Signs Multi-Million dollar Line of Credit Agreement with Western Technology Investment Read More »

Study Results Evaluating the Correction of Atrophic Scars with Artefill Presented at 2010 Orlando Dermatology Conference

April 4, 2013

Study Suggests Artefill® Provides an Effective and Potentially Long-Lasting Treatment Option for Acne Scar Patients SAN DIEGO, CA – January 18, 2010 – Suneva Medical, a privately-held aesthetic medical device company, provided a research grant to support an investigator-sponsored research study to evaluate the degree of correction and patient satisfaction after injection of atrophic scars …

Study Results Evaluating the Correction of Atrophic Scars with Artefill Presented at 2010 Orlando Dermatology Conference Read More »

Suneva Medical Announces Positive Interim Data from Five-Year Safety and Patient Satisfaction Study on Artefill®

April 4, 2013

Study Suggests ArteFill Is As Safe as Other Dermal Fillers for Nasolabial Fold Correction – Data Presented at Maui Derm 2010 Meeting – MAUI, HAWAII — January 25, 2010 – Suneva Medical, a privately-held aesthetic medical device company, today announced 18-month interim results from its prospective, open-label, five-year safety and patient satisfaction study on ArteFill …

Suneva Medical Announces Positive Interim Data from Five-Year Safety and Patient Satisfaction Study on Artefill® Read More »

Two Studies Find Artefill® to Be a Long-Term Treatment Option for Facial Lipoatrophy

April 4, 2013

Investigator-Initiated Studies Examine Artefill’s Use with Age-Related and HIV-Associated Facial Lipoatophy Patients SAN DIEGO, CA – February 2, 2010 – Suneva Medical, a privately-held aesthetic medical device company, today announced that two clinical studies suggest Artefill may be a safe, effective, long-term treatment option for age-related and HIV lipoatrophy patients. The studies were presented at …

Two Studies Find Artefill® to Be a Long-Term Treatment Option for Facial Lipoatrophy Read More »

Suneva Medical Announces Publication of ArteFill® Five-Year Safety and Patient Satisfaction Study Interim Results in Dermatologic Surgery

April 4, 2013

SAN DIEGO, CA – May 5, 2010 – Suneva Medical, a privately-held aesthetic medical device company, today announced the publication of interim results from its long-term study on ArteFill in the May 2010 issue of Dermatologic Surgery, the Journal of the American Society of Dermatologic Surgery. The study highlights the safety profile (adverse events, granuloma …

Suneva Medical Announces Publication of ArteFill® Five-Year Safety and Patient Satisfaction Study Interim Results in Dermatologic Surgery Read More »

Artefill® Featured on The Doctors Television Show

April 4, 2013

®trong>SAN DIEGO, CA – May 7, 2010 – Suneva Medical, a privately-held aesthetic medical device company, today announced that its lead product Artefill, was featured on the nationally syndicated CBS medical talk show, “The Doctors” on May 6th. The “New Body Breakthroughs” segment showcased Artefill as an effective and longer lasting solution for smile line …

Artefill® Featured on The Doctors Television Show Read More »

Important Safety Information

Bellafill®
Bellafill® is indicated for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. Patients who have had a positive reaction to the Bellafill® Skin Test, have a history of severe allergies, have known bovine collagen allergies, are allergic to lidocaine, have bleeding disorders or are prone to thick scar formation and/or excessive scarring should not receive Bellafill®. The safety of Bellafill® for use during pregnancy, breastfeeding, or in patients under 21 has not been established. You may experience temporary swelling, redness, pain, bruising, lumps/bumps, itching, and discoloration at the treatment site. These side effects are usually transient and typically resolve within 1–7 days. You may experience lumps/bumps/papules that may occur more than one month after injection and that may persist. Less common side effects include rash and itching more than 48 hours after treatment, persistent swelling or redness, lumps/bumps, acne, and increased sensitivity at treatment sites. Infrequently, granulomas may occur and may be treated by your licensed physician provider. Be sure to call your licensed provider immediately if you notice any unusual skin reactions around the treatment area. Based on the 5-year Post-Approval Study on nasolabial folds with 1,008 patients, long-term safety of Bellafill® for up to 5 years has been established.

PUREGRAFT
This product is certified as a medical device in the European Union under the Medical Device Directive 93/42/EEC by SGS CE0120, exclusively for the indication of autologous fat transfer. Other non-medical uses ascribed to this device such as aesthetic body contouring are not within the scope of CE certification, and users should be aware product performance and/or safety has not been evaluated by SGS for those purposes.

Suneva Medical HD PRP
REGULATORY STATUS: FDA-cleared 510(k) Class II medical device. Healeon HD PRP is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of peripheral blood at the patient point of care. The PRP is mixed with autograft and/orallograft bone prior to application to a bony defect for improving handling characteristics. 510(k) number: BK170136

For more safety information, please consult with your physician and the patient labeling that can be found by visiting our website www.bellafill.com.
Toll-free call (U.S. & Canada): 844-Bellafill (844-235-5234).
Local calls: 858-550-9999. International calls: ++ 858-550-9999.